Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAM-MS trial of HSCT versus high-efficacy disease-modifying therapy in aggressive relapsing-remitting multiple sclerosis
NL-OMON59216Phase 3Active, not recruiting
- Sponsor
- Helse Bergen
- Start
- Dec 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of antithymocyte immunoglobulin, alemtuzumab, cladribine and ocrelizumab in multiple sclerosis (MS) (2 arms), sponsored by Helse Bergen. Primary endpoints: No evidence of disease activity at 96 weeks and No evidence of disease activity at 240 weeks. Started Dec 2019; status: active, not recruiting.
02
Drugs
antithymocyte immunoglobulinalemtuzumabcladribineocrelizumab
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NL-OMON59216.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59216.